J Korean Ophthalmol Soc.  2011 Jun;52(6):702-708. 10.3341/jkos.2011.52.6.702.

Prophylactic Effects of a Fixed Dorsolamide/Timolol Combination on IOP Elevation before Intravitreal Anti-VEGF Injection

• Lim YJ
• Kim JM
• Han YS
• Chung IY
• Park JM

• KMID: 2214642
• DOI: http://doi.org/10.3341/jkos.2011.52.6.702

Abstract

PURPOSE
The purpose of the present study was to investigate the prophylactic effects of a fixed combination of dorsolamide/timolol on intraocular pressure (IOP) elevation before intravitreal anti-VEGF injection.
METHODS
A prospective, randomized clinical trial was conducted on 91 eyes of 91 patients undergoing intravitreal anti-VEGF injection. The eyes were randomly divided into 2 groups, the eyes which had used the fixed prophylactic dorsolamide/timolol combination (group 1, 58 eyes) and the eyes which had not used the combination (group 2, 15 eyes). The IOP was measured one hour and 5 minutes prior to the procedure, 5 minutes interval up to 30 minutes after the procedure and one hour, 1 day, 7 days, and one month after the procedure. The IOP changes were analyzed.
RESULTS
The mean 5 minutes and 30 minutes postoperative IOPs were 14.12 +/- 4.18 mm Hg and 10.87 +/- 1.58 mm Hg in group 1 and 28.21 +/- 3.16 mm Hg and 17.48 +/- 2.34 mm Hg in group 2, respectively. After IVBI, the mean 5 min postoperative IOP was 12.17 +/- 1.13 mm Hg in group 1 and 27.12 +/- 3.35 mm Hg in group 2. After IVRI, the mean 5 minutes postoperative IOP was 15.98 +/- 4.14 mm Hg in group 1 and 25.19 +/- 1.04 mm Hg in group 2.
CONCLUSIONS
Prophylactic use of a fixed dorsolamide/timolol combination before intravitreal anti-VEGF injection is an easy and safe method of preventing IOP elevation immediately after intravitreal injection of bevacizumab or ranibizumab.

Keyword

Bevacizumab; Dorsolamide; IOP; Ranibizumab; Timolol

MeSH Terms

Antibodies, Monoclonal, Humanized
Eye
Humans
Intraocular Pressure
Intravitreal Injections
Prospective Studies
Timolol
Bevacizumab
Ranibizumab
Antibodies, Monoclonal, Humanized
Timolol

Figure

• 

  Figure 1. Serial change of mean IOP in both groups. * IOP = intraocular pressure.

Reference

References

1. Lew YJ, Park HJ, Lee TG, et al. Primary combined photodynamic therapy and intravitreal bevacizumab injection for neovascular age-related macular degeneration. J Korean Ophthalmol Soc. 2010; 51:35–41.

2. Smit DP, Meyer D. Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol. 2007; 1:273–84.

3. el Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010; 248:779–84.

4. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010; 21:178–83.

5. Nunes RP, Nóbrega MJ, De Novelli FJ, et al. Causes of interruption of bevacizumab therapy in age-related macular degeneration. Arq Bras Oftalmol. 2010; 73:146–9.

6. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intra-vitreal triamcinolone acetonide injection. Korean J Ophthalmol. 2005; 19:122–7.

7. Bashshur ZF, Terro AM, Haibi CP, et al. Intravitreal triamcinolone acetonide: Pattern of secondary intraocular pressure rise and possible risk factors. Clin Ophthalmol. 2008; 2:269–74.

8. Pong JC. Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol. 2008; 246:463–4.

9. Arnavielle S, Creuzot-Garcher C, Bron AM. Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol. 2007; 245:345–50.

10. Cheung CM, Durrani OM, Murray PI. The safety of anterior chamber paracentesis in patients with uveitis. Br J Ophthalmol. 2004; 88:582–3.

11. Lee SJ, Lee JJ, Kim SD. Multiple retinal hemorrhage following anterior chamber paracentesis in uveitic glaucoma. Korean J Ophthalmol. 2006; 20:128–30.

12. Astam N, Batioğ lu F, Ozmert E. Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. Int Ophthalmol. 2009; 29:543–8.

13. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113:1695.

14. Atchaneeyasakul LO, Trinavarat A. Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol. 2010; 30:497–9.

15. Brouzas D, Koutsandrea C, Moschos M, et al. Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by controlateral sympathetic ophthalmia. Clin Ophthalmol. 2009; 3:457–9.

16. Artunay O, Yuzbasioglu E, Rasier R, et al. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye. 2009; 23:2187–93.

17. Sharei V, Höhn F, Köhler T, et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010; 20:174–9.

18. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010; 26:105–10.

19. Chang W, Chung M. Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection. Eur J Ophthalmol. 2007; 17:776–9.

20. Seong HK, Lee JM, Park YS, Lee BR. Immediate natural course of IOP after IVTA and the effect of preoperative ocular massage. J Korean Ophthalmol Soc. 2007; 48:808–14.

21. Theoulakis PE, Lepidas J, Petropoulos IK, et al. Effect of brimoni-dine/timolol fixed combination on preventing the short-term intra-ocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd. 2010; 227:280–4.

22. Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009; 18:658–61.

23. Shonat RD, Wilson DF, Riva CE, Cranstoun SD. Effect of acute increases in intraocular pressure on intravascular optic nerve head oxygen tension in cats. Invest Ophthalmol Vis Sci. 1992; 33:3174–80.

24. Că lugă ru D, Că lugă ru M. Fixed combinations of glaucoma medications. Oftalmologia. 2008; 52:23–31.

25. Yeh J, Kravitz D, Francis B. Rational use of the fixed combination of dorzolamide – timolol in the management of raised intraocular pressure and glaucoma. Clin Ophthalmol. 2008; 2:389–99.

26. Shim JC, Choe CM, Seong GJ. A comparision of short term use ef-fects and satety of timoptic(R) with those of cosopt(R) in normal Korean. J Korean Ophthalmol Soc. 2002; 43:1206–11.

27. Miglior S, Grunden JW, Kwok K; Xalacom/Cosopt European Study Group. Efficacy and safety of fixed combinations of latano-prost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye. 2010; 24:1234–42.

28. Teus MA, Miglior S, Laganovska G, et al. Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009; 3:629–36.

29. Eakins KE, Whitelocke RA, Bennett A, Martenet AC. Prostaglandin- like activity in ocular inflammation. Br Med J. 1972; 3:452–3.

30. Jampol LM. Aphakic cystoid macular edema. A hypothesis. Arch Ophthalmol. 1985; 103:1134–5.